 UNIONDALE, N.Y., Feb. 09, 2021 GLOBE NEWSWIRE -- Angion Biomedica Corp. Angion NASDAQ:ANGN, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the closing of 117 million in gross proceeds from its previously announced initial public offering and concurrent private placement. 